These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 12884299)

  • 1. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
    Xanthou G; Duchesnes CE; Williams TJ; Pease JE
    Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
    Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation.
    Xanthou G; Williams TJ; Pease JE
    Eur J Immunol; 2003 Oct; 33(10):2927-36. PubMed ID: 14515277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alanine scanning mutagenesis of the chemokine receptor CCR3 reveals distinct extracellular residues involved in recognition of the eotaxin family of chemokines.
    Duchesnes CE; Murphy PM; Williams TJ; Pease JE
    Mol Immunol; 2006 Mar; 43(8):1221-31. PubMed ID: 16102831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I-TAC/CXCL11 is a natural antagonist for CCR5.
    Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
    J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
    Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
    J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel, selective, and orally available antagonist for CC chemokine receptor 3.
    Morokata T; Suzuki K; Masunaga Y; Taguchi K; Morihira K; Sato I; Fujii M; Takizawa S; Torii Y; Yamamoto N; Kaneko M; Yamada T; Takahashi K; Shimizu Y
    J Pharmacol Exp Ther; 2006 Apr; 317(1):244-50. PubMed ID: 16339911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3.
    Loetscher P; Pellegrino A; Gong JH; Mattioli I; Loetscher M; Bardi G; Baggiolini M; Clark-Lewis I
    J Biol Chem; 2001 Feb; 276(5):2986-91. PubMed ID: 11110785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
    Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
    J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down-regulation in a ligand-dependent manner.
    Sabroe I; Jorritsma A; Stubbs VE; Xanthou G; Jopling LA; Ponath PD; Williams TJ; Murphy PM; Pease JE
    Eur J Immunol; 2005 Apr; 35(4):1301-10. PubMed ID: 15739168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells.
    Ranjbaran H; Wang Y; Manes TD; Yakimov AO; Akhtar S; Kluger MS; Pober JS; Tellides G
    Circulation; 2006 Sep; 114(12):1293-300. PubMed ID: 16940188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13.
    Andrew DP; Chang MS; McNinch J; Wathen ST; Rihanek M; Tseng J; Spellberg JP; Elias CG
    J Immunol; 1998 Nov; 161(9):5027-38. PubMed ID: 9794440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies.
    De Paepe B; De Keyzer K; Martin JJ; De Bleecker JL
    Acta Neuropathol; 2005 Jun; 109(6):576-82. PubMed ID: 15937690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloning and characterization of the guinea pig eosinophil eotaxin receptor, C-C chemokine receptor-3: blockade using a monoclonal antibody in vivo.
    Sabroe I; Conroy DM; Gerard NP; Li Y; Collins PD; Post TW; Jose PJ; Williams TJ; Gerard CJ; Ponath PD
    J Immunol; 1998 Dec; 161(11):6139-47. PubMed ID: 9834099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.
    Kao J; Kobashigawa J; Fishbein MC; MacLellan WR; Burdick MD; Belperio JA; Strieter RM
    Circulation; 2003 Apr; 107(15):1958-61. PubMed ID: 12695288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-gamma.
    Dajotoy T; Andersson P; Bjartell A; Löfdahl CG; Tapper H; Egesten A
    J Leukoc Biol; 2004 Sep; 76(3):685-91. PubMed ID: 15197236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo.
    Stanford MM; Issekutz TB
    J Leukoc Biol; 2003 Nov; 74(5):791-9. PubMed ID: 12960247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions.
    Bochner BS; Hudson SA; Xiao HQ; Liu MC
    J Allergy Clin Immunol; 2003 Nov; 112(5):930-4. PubMed ID: 14610482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design.
    Trotta T; Costantini S; Colonna G
    Mol Immunol; 2009 Dec; 47(2-3):332-9. PubMed ID: 19800124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
    Müller M; Carter S; Hofer MJ; Campbell IL
    Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.